Abstract
The most common PET radioisotopes, both in the literature and in clinical practice, are the cyclotron produced 11C and 18F, giving rise to tracers with minimal chemical changes with respect to the original biological molecule. However, the short half-life of these two radioisotopes and the relatively complex chemistry of their incorporation into the molecules of interest limits the number of molecules that really can be labelled in a suitable length of time. 68Ga is a positron emitter, produced by a 68Ge/68Ga generator rending the production of its radiopharmaceuticals independent of an onsite cyclotron. This paper covers the main aspects of the Ga3+ coordination chemistry together with the state of art of its radiopharmacy.
Keywords: Bioconjugates, PET imaging, nuclear probes, 68Ge/68Ga generator, gallium-68, MSH, Peptides, Imaging, Antibodies
Current Radiopharmaceuticals
Title: Gallium-68: A New Trend in PET Radiopharmacy
Volume: 5 Issue: 2
Author(s): M. Isabel M. Prata
Affiliation:
Keywords: Bioconjugates, PET imaging, nuclear probes, 68Ge/68Ga generator, gallium-68, MSH, Peptides, Imaging, Antibodies
Abstract: The most common PET radioisotopes, both in the literature and in clinical practice, are the cyclotron produced 11C and 18F, giving rise to tracers with minimal chemical changes with respect to the original biological molecule. However, the short half-life of these two radioisotopes and the relatively complex chemistry of their incorporation into the molecules of interest limits the number of molecules that really can be labelled in a suitable length of time. 68Ga is a positron emitter, produced by a 68Ge/68Ga generator rending the production of its radiopharmaceuticals independent of an onsite cyclotron. This paper covers the main aspects of the Ga3+ coordination chemistry together with the state of art of its radiopharmacy.
Export Options
About this article
Cite this article as:
Isabel M. Prata M., Gallium-68: A New Trend in PET Radiopharmacy, Current Radiopharmaceuticals 2012; 5 (2) . https://dx.doi.org/10.2174/1874471011205020142
DOI https://dx.doi.org/10.2174/1874471011205020142 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)
Anti-Cancer Agents in Medicinal Chemistry Novel Beta-Lactam Antibiotics Derivatives: Their New Applications as Gene Reporters, Antitumor Prodrugs and Enzyme Inhibitors
Mini-Reviews in Medicinal Chemistry Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
Current Cancer Drug Targets Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Hologram QSAR Studies of N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides Derivatives as Selective Peripheral Benzodiazepine Receptor Ligands
Letters in Drug Design & Discovery Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Apoptosis in Drug Response
Current Pharmacogenomics Transplantation of Adipose Tissue-Derived Stem Cells for Treatment of Focal Cerebral Ischemia
Current Neurovascular Research <i>DBX2</i> Promotes Glioblastoma Cell Proliferation by Regulating <i>REST</i> Expression
Current Pharmaceutical Biotechnology Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology
Current Molecular Medicine